Bristol Myers Squibb's Mezigdomide Combination Shows PFS Boost in Multiple Myeloma Trial

Event summary

  • Bristol Myers Squibb's SUCCESSOR-2 Phase 3 trial showed oral mezigdomide (MeziKd) combination improved progression-free survival (PFS) in relapsed/refractory multiple myeloma patients.
  • The study met its primary endpoint with statistically significant and clinically meaningful PFS improvement over carfilzomib and dexamethasone alone (Kd).
  • Safety profile aligned with known mezigdomide characteristics; patients continue long-term follow-up for survival and safety data.
  • Results to be presented at future medical meetings and shared with health authorities for potential regulatory submissions.

The big picture

This success reinforces Bristol Myers Squibb's leadership in multiple myeloma, where treatment resistance remains a critical unmet need. The CELMoD platform represents a strategic pivot toward next-generation oral therapies, potentially expanding the company's dominance in blood cancers. The results also highlight the growing importance of targeted protein degradation as a modality for previously 'undruggable' targets.

What we're watching

Regulatory Pathway
Whether the PFS data will be sufficient for accelerated approval and the timeline for potential regulatory submissions.
Commercial Potential
How MeziKd will position against existing multiple myeloma treatments, particularly for lenalidomide-exposed patients.
Pipeline Strategy
The pace at which Bristol Myers Squibb advances its targeted protein degradation platform across other hematologic and oncologic indications.